Anti-IgE (Omalizumab), Humanized Antibody

Anti-IgE (Omalizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: Omalizumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that binds with a higher affinity to free IgE and inhibits the binding of free IgE to high-affinity IgE receptor (FcεRI) expressed on mast cells and basophils. This results in the downregulation of FcεRI and decreased release of mediators of inflammatory response. Omalizumab neither binds directly to the high-affinity IgE receptor (FcεRI) nor the receptor-bound IgE. This monoclonal antibody was developed by Tanox, Novartis, and Genentech and received approval from the FDA in 2009 for the treatment of allergic asthma. Recently, it has been approved for the treatment of chronic spontaneous urticaria (CIU).

Immunogen Sequence:Omalizumab

Target Alternative Name:IGE25, Olizumab, pSVIE26, rhuMab-E25, IGHE

Species Reactivities:Human

Tag Line:Omalizumab is a recombinant DNA-derived humanized monoclonal antibody that selectively targets free human IgE and prevents its association with the receptor FcεRI, thereby reducing sensitivity to allergens. This monoclonal antibody received FDA approval to treat allergic asthma

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:In vitro studies

Positive Control:/

Application And Usages:In vitro studies

Handling:The antibody solution should be gently mixed before use.